Anti-CGRP antibodies and small-molecule CGRP receptor antagonists work through fundamentally different mechanisms, which may explain differences in their clinical efficacy, safety, and tolerability.
Distinct mechanisms of actionReceptor-targeting drugs block multiple peptides while ligand antibodies selectively block only CGRP
What the researchers found
CGRP ligand antibodies and receptor-targeting agents have distinct mechanisms: receptor antibodies and gepants block multiple peptides and receptors, while ligand antibodies selectively block only CGRP signaling.
Why it matters
Understanding these mechanistic differences helps explain why patients may respond differently to various CGRP-targeting migraine drugs and could guide treatment selection for individual patients.
The numbers in context
6 approved drugs: 3 anti-CGRP mAbs, 1 anti-receptor mAb, 2 gepants; distinct CGRP pathway modulation mechanisms.
How the study worked
In vitro comparison using binding assays, cAMP functional assays, and imaging/internalization assays with human CGRP and AMY1 receptors.
Who was studied
Migraine patients across clinical trials of CGRP-targeting therapeutics
What this study cannot tell us
In vitro study that may not fully capture the complexity of in vivo pharmacology. Clinical implications of these mechanistic differences remain to be confirmed in head-to-head clinical trials.
How to read the evidence
Well-designed in vitro mechanistic study providing strong pharmacological evidence, though clinical translation remains to be confirmed.
When this study was published
Published in 2021, when several CGRP-targeting drugs were already FDA-approved and in clinical use.
The bigger picture
The CGRP pathway revolution has transformed migraine treatment, but these drugs are often discussed as if they work the same way. This study reveals important mechanistic distinctions that could affect clinical outcomes and help personalize migraine therapy.
Questions still open
- Do these mechanistic differences translate into clinically meaningful differences in migraine prevention efficacy?
- Could the broader receptor activity of erenumab contribute to its side effect profile?
- Should migraine patients who fail one class of CGRP therapy be switched to a mechanistically distinct class?
Common questions
Why do different CGRP migraine drugs work differently?
If one CGRP migraine drug doesn't work, should I try another?
Read the original research
Migraine therapeutics differentially modulate the CGRP pathway.
Cephalalgia : an international journal of headache, 41(5), 499-514
Citation
Bhakta, Minoti; Vuong, Trang; Taura, Tetsuya; Wilson, David S; Stratton, Jennifer R; Mackenzie, Kimberly D. (2021). Migraine therapeutics differentially modulate the CGRP pathway.. Cephalalgia : an international journal of headache, 41(5), 499-514. https://doi.org/10.1177/0333102420983282